60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1).
Publication
, Journal Article
Yeh, T; Jacobs, V; Angell, H; Geradts, J; Hou, J; Karakunnel, J; Barrett, C
Published in: J Thorac Oncol
April 2016
Duke Scholars
Published In
J Thorac Oncol
DOI
EISSN
1556-1380
Publication Date
April 2016
Volume
11
Issue
4 Suppl
Start / End Page
S80 / S81
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Yeh, T., Jacobs, V., Angell, H., Geradts, J., Hou, J., Karakunnel, J., & Barrett, C. (2016). 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1). J Thorac Oncol, 11(4 Suppl), S80–S81. https://doi.org/10.1016/S1556-0864(16)30173-3
Yeh, T., V. Jacobs, H. Angell, J. Geradts, J. Hou, J. Karakunnel, and C. Barrett. “60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1).” J Thorac Oncol 11, no. 4 Suppl (April 2016): S80–81. https://doi.org/10.1016/S1556-0864(16)30173-3.
Yeh T, Jacobs V, Angell H, Geradts J, Hou J, Karakunnel J, et al. 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1). J Thorac Oncol. 2016 Apr;11(4 Suppl):S80–1.
Yeh, T., et al. “60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1).” J Thorac Oncol, vol. 11, no. 4 Suppl, Apr. 2016, pp. S80–81. Pubmed, doi:10.1016/S1556-0864(16)30173-3.
Yeh T, Jacobs V, Angell H, Geradts J, Hou J, Karakunnel J, Barrett C. 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1). J Thorac Oncol. 2016 Apr;11(4 Suppl):S80–S81.
Published In
J Thorac Oncol
DOI
EISSN
1556-1380
Publication Date
April 2016
Volume
11
Issue
4 Suppl
Start / End Page
S80 / S81
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology